Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Medtech is back.

After stabilizing in the third quarter, medtech stocks gained significant momentum in the fourth quarter. Many investors have yet to recognize this positive performance trend. Although the Bellevue Medtech & Services Fund has delivered a positive return of +1.0% year to date, it still lags well behind the global equity market (+17.9%) and the US technology market (+19.5%).
16.11.2026 - Marcel Fritsch
Total returnGlobal equities 
(MXWO net)
Nasdaq-100 
(NDX)
Bellevue Medtech & 
Services | I-EUR
Q3 2026+2.6%+1.3%+2.3%
Current Q4 2026+2.0%-4.6%+16.1%
Year-to-date
2026
+17.9%+19.5%+1.0%

Source: Bloomberg, data as per November 11, 2026 in EUR

AI is no longer a one-way trade
What weighed on the medtech sector’s performance in the first half of the year has now become an important driver of outperformance. Investors increasingly recognize that AI stocks cannot rise indefinitely. Even Goldman Sachs states in a headline: «AI Is No Longer a One-Way Trade.» Capital is seeking quality, growth and valuation discipline, and that is precisely what the medtech sector offers.

Valuations leave considerable room for upside
The fundamental investment drivers have changed little over the years. For the Bellevue Medtech & Services Fund, we continue to expect average annual revenue growth of around 8% and earnings growth of 13% through 2029. Even after the recent market recovery, the medtech sector remains attractively valued. Trading at a price-to-earnings ratio of 19.6x based on expected earnings over the next 12 months, it stands around 18% below its average since 2022 (23.9x) and around 27% below its pre-Covid-19 level (27.0x).

open glightbox
All data in USD, analysis period March 7, 2022 to September 30, 2026
MSCI Healthcare Equipment & Supplies (Medtech): MXWO0HE Index
Source: Bellevue Asset Management, Bloomberg (data)

 

US elections provide a tailwind
Following the Democrats’ victory in the midterm elections, investors see hospitals (as customers of medtech companies), and consequently the medtech sector, as beneficiaries, for example through improved funding for Medicaid and the Affordable Care Act (ACA). At the same time, sweeping policy changes are unlikely to pass with a Republican US president in the White House holding veto power. We therefore consider the risk of regulatory intervention in the healthcare sector to be limited. By contrast, market participants see rising regulatory risks in the technology sector. The chart below shows a strong negative correlation between the medtech and semiconductor sectors.

 

open glightbox
Source: Bloomberg, data as of 11 November 2026 in EUR

Our conclusion
The rotation has only just begun: The performance gap relative to the global equity market and the technology sector points to substantial remaining catch-up potential. For investors reviewing their equity allocation, medtech offers an attractive combination of defensive growth, strong resilience, attractive valuations and low correlation with the technology sector. In our view, investors seeking to reduce their equity exposure should do so primarily outside the medtech sector.

open glightbox
Source: Bellevue Asset Management AG, Bloomberg. Data as of 11 November 2026 in EUR. 
Past performance is not a reliable indicator of future results.

These investment strategies might interest you